NEVRO CORP's ticker is NVRO and the CUSIP is 64157F103. A total of 218 filers reported holding NEVRO CORP in Q3 2020. The put-call ratio across all filers is 1.11 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $15,000 | -11.8% | 331 | +38.5% | 0.00% | – |
| Q1 2022 | $17,000 | -15.0% | 239 | -4.0% | 0.00% | – |
| Q4 2021 | $20,000 | +33.3% | 249 | +88.6% | 0.00% | – |
| Q3 2021 | $15,000 | -58.3% | 132 | -39.4% | 0.00% | – |
| Q2 2021 | $36,000 | +176.9% | 218 | +139.6% | 0.00% | – |
| Q1 2021 | $13,000 | -56.7% | 91 | -46.8% | 0.00% | – |
| Q4 2020 | $30,000 | +25.0% | 171 | -1.7% | 0.00% | – |
| Q3 2020 | $24,000 | +20.0% | 174 | +3.0% | 0.00% | – |
| Q2 2020 | $20,000 | +400.0% | 169 | +267.4% | 0.00% | – |
| Q3 2019 | $4,000 | -20.0% | 46 | -37.0% | 0.00% | – |
| Q2 2019 | $5,000 | 0.0% | 73 | 0.0% | 0.00% | – |
| Q1 2019 | $5,000 | 0.0% | 73 | -37.6% | 0.00% | – |
| Q4 2018 | $5,000 | -28.6% | 117 | 0.0% | 0.00% | – |
| Q3 2018 | $7,000 | -22.2% | 117 | 0.0% | 0.00% | – |
| Q2 2018 | $9,000 | +800.0% | 117 | +1571.4% | 0.00% | – |
| Q1 2018 | $1,000 | – | 7 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Consonance Capital Management LP | 1,446,333 | $82,441,000 | 4.44% |
| Asymmetry Capital Management, L.P. | 31,379 | $1,789,000 | 1.65% |
| TIRSCHWELL & LOEWY INC | 194,470 | $11,085,000 | 1.38% |
| ZEVENBERGEN CAPITAL INVESTMENTS LLC | 673,480 | $38,388,000 | 1.22% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 525,040 | $29,927,000 | 1.07% |
| Orbimed Advisors | 1,357,691 | $77,388,000 | 0.93% |
| Sio Capital Management, LLC | 45,091 | $2,570,000 | 0.88% |
| PURA VIDA INVESTMENTS, LLC | 60,000 | $3,420,000 | 0.72% |
| SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC | 159,800 | $9,109,000 | 0.62% |
| Endurant Capital Management LP | 24,171 | $1,378,000 | 0.61% |